Biogen Idec 1st-qtr 2014 revenue leaps 51%, driven by Tecfidera and MS franchise

23 April 2014

US biotech firm Biogen Idec (Nasdaq: BIIB) first-quarter 2014 results today, including revenue of $2.1 billion, a 51% increase compared to the first quarter of 2013, just beating analysts’ consensus estimates of $2 billion. The firm’s shares dipped 1.9% to $300.33 by mid-morning trading.

The revenue growth year-over-year was driven by strong performance of the new, oral, multiple sclerosis drug Tecfidera (dimethyl fumarate) and from recording 100% of Tysabri (natalizumab) revenues following Biogen’s acquisition of complete rights for the asset in the second quarter of 2013, the company noted.

First quarter 2014 non-generally accepted accounting principles (GAAP) diluted earnings per share (EPS) were $2.47, an increase of 25%, missing the $2.55 average of 23 analysts’ estimates compiled by Bloomberg. Non-GAAP net income attributable to Biogen Idec for the year was $587 million, up 25% over the first quarter of 2013.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology